Dr Reddys Laboratories has reported results for third quarter ended December 31, 2012.
The company has posted growth of over 3-fold in its net profit at Rs 346.64 crore for the quarter as compared to Rs 108.03 crore for the same quarter in the previous year. Total income from operation of the company has increased by 33.97% at Rs 2186.30 crore for quarter under review as compared to Rs 1631.86 crore for the quarter ended December 31, 2011.
The company, on consolidated basis, posted a fall of 29.17% in its net profit at Rs 363.31 crore for the quarter as compared to Rs 512.96 crore for the same quarter in the previous year. However, total income of the company increased by 3.69% at Rs 2888.47 crore for quarter under review as compared to Rs 2785.67 crore for the quarter ended December 31, 2011.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1872.60 |
| Dr. Reddys Labs. | 1376.30 |
| Cipla | 1453.50 |
| Zydus Lifesciences | 1121.65 |
| Lupin | 2407.45 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: